Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q5MY95
UPID:
ENTP8_HUMAN
Alternative names:
-
Alternative UPACC:
Q5MY95; A2BG17; Q6UVZ0
Background:
Ectonucleoside triphosphate diphosphohydrolase 8 (ENTPD8) is a pivotal enzyme in hepatic nucleotide metabolism, catalyzing the hydrolysis of gamma- and beta-phosphate residues of nucleotides. This enzyme exhibits specificity towards ATP, ADP, UTP, and UDP, playing a crucial role in regulating extracellular nucleotide concentrations.
Therapeutic significance:
Understanding the role of Ectonucleoside triphosphate diphosphohydrolase 8 could open doors to potential therapeutic strategies. Its central function in nucleotide metabolism makes it a promising target for modulating disease processes through the manipulation of extracellular nucleotide levels.